TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05896449

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PSMA-11 PET/CT
Description: The PET/CT image acquisition was performed from the skull to the mid-thigh (3-min per bed position, 3 iterations, 21 subsets) with a CT scan (120 kV, 170mAs reference) with dose modulation for anatomic correlation (CARE dose 4D) and attenuation correction on a Biograph 64 TruePoint (Siemens Medical Solutions Inc., USA) 60 min post injection of \[68Ga\]Ga-PSMA-11 (2 MBq per kg body weight).
Study: NCT03883594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-assisted Stepped-care
Description: Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
Study: NCT00592033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen from a portable concentrator
Description: 2 l/minute during exercise
Study: NCT00777621

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calorie Restriction
Description: This group will undergo a 20% reduction in energy intake without any change in energy expenditure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: This group will undergo a 20% increase in energy expenditure by exercising without any change in energy intake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie Restriction and Exercise
Description: This group will undergo 10% reduction in energy intake and a 10% increase in energy expenditure via exercise.
Study: NCT04093843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: NeuroStar TMS Therapy
Study: NCT04153773

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT
Description: The degree of physical disability was assessed by using the Expanded Disability Status Scale (EDSS). The EDSS score ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.~Neurocognitive functions were evaluated using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) that includes the following tests:~1. Symbol Digit Modalities Test (SDMT) that is used for assessment of information processing speed.~2. California Verbal Learning Test - 2nd edition (CVLT-II) .~3. Brief Visuospatial Memory Test-Revised (BVMT-R)~OCT assessment was performed by spectral domain-optical coherence tomography to assess the retinal nerve fiber layer thickness and macular volume in humans .~Each eye for every patient was assessed by measuring the thickness of RNFL and GCC, respecting presence or absence of the previous history of optic neuritis (ON).

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT
Description: The degree of physical disability was assessed by using the Expanded Disability Status Scale (EDSS). The EDSS score ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.~Neurocognitive functions were evaluated using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) that includes the following tests:~1. Symbol Digit Modalities Test (SDMT) that is used for assessment of information processing speed.~2. California Verbal Learning Test - 2nd edition (CVLT-II) .~3. Brief Visuospatial Memory Test-Revised (BVMT-R)~OCT assessment was performed by spectral domain-optical coherence tomography to assess the retinal nerve fiber layer thickness and macular volume in humans .~Each eye for every patient was assessed by measuring the thickness of RNFL and GCC, respecting presence or absence of the previous history of optic neuritis (ON).
Study: NCT02680925

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lung protective ventilation
Description: TV 4 ml/kg during one lung ventilation and 6 ml/kg during two-lung ventilation with PEEP of 6 cmH2O

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional ventilation
Description: TV 8 ml/kg during one lung ventilation and 10 ml/kg during two-lung ventilation without PEEP
Study: NCT02760979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Denosumab treatment one year after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Serum one year after surgery
Study: NCT00887120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir standard dose According to WHO simplified dosing table
Description: * BW 6-7.9 kg: 1.5 mL oral q 12 hr~* BW 8.0-16.9 kg: 2.0 ml oral q 12 hr~* BW 17.0-19.9 kg: 2.5 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 4.0 ml oral q 12 hr~* BW \> 35 kg: 5.0 ml oral q 12 hr~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)
Description: * BW 6-7.9 kg: 1.0 mL oral q 12 hr~* BW 8.0-16.9 kg: 1.5 ml oral q 12 hr~* BW 17.0-19.9 kg: 1.8 ml oral q 12 hr~* BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr~* BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr~* BW 30.0-34.9 kg: 3.0 ml oral q 12 hr~* BW \> 35 kg: 3.5 ml oral q 12 h~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)
Study: NCT02228720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Propel Nova Sinus Implant
Description: Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
Study: NCT00130195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study: NCT00359138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: 5 mg tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levocetirizine
Description: 5 mg capsule once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine placebo tablet
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Desloratadine placebo tablet
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine placebo capsule
Description: once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levocetirizine placebo capsule
Description: once daily
Study: NCT04526236

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methadone Injectable Product
Description: Perioperative use of placebo for pain management and remifentanil during the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Injectable Product
Description: Perioperative use of placebo for pain management and remifentanil during the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Injectable Product
Description: Perioperative use of placebo for pain management and remifentanil during the surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone Injectable Product
Description: Perioperative use of placebo for pain management and remifentanil during the surgery.
Study: NCT00577109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5mg/kg iv on day 1 of each 2 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180mg/m2 iv on day 1 of each 2 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200mg/m2 iv on day 1 of each 2 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FU
Description: 400mg/m2 iv on day 1 of each 2 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle
Study: NCT01979536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT and IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT and IV
Study: NCT03208764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Subjects will be treated with 91 thirty minute sessions of 160 ppm Nitric Oxide with at least 3 hours between each session.
Study: NCT01538628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpaceOAR System
Description: Fiducial marker placement followed by randomization to treatment group, i.e., 10mL SpaceOAR hydrogel injection, or control group, i.e., no injection of SpaceOAR hydrogel.
Study: NCT01978821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Study: NCT03620890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Protamine Hagedorn (NPH)
Description: NPH will peak between 4-12 hours after injection with a duration of action around 14 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Detemir insulin
Description: Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
Study: NCT02516787

Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight

Intervention type: OTHER
Group type: OTHER
Intervention: EEG measurement
Description: Electro cortical power in alpha frequency ranges (EEG-LORETA)

Intervention type: OTHER
Group type: OTHER
Intervention: NIRS measurements
Description: Brain tissue oxygenation ( oxy- or deoxygenated hemoglobin values) - NIRS
Study: NCT04946279

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual/standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive conversation tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies - Baseline and follow-up questionnaires

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies - Baseline and follow-up questionnaires
Study: NCT01999569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole administered daily through the time of ovulation.
Study: NCT03409848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Addition of Nivolumab to Standard therapy (chemotherapy and Trastuzumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
Study: NCT02823795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Patients will get motivational interviewing sessions by a patient activation coach (medical social workers and/or nurses trained in motivational interviewing and in the intervention) in five post hospital discharge sessions (whereof one face-to-face, four by phone) aiming to increase patient motivation to become active in self-management (medication management, care plan/follow-up, symptoms/signs of worsening condition, contacts with health care provider).
Study: NCT01740960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delta-9-tetrahydrocannabinol
Description: During the intervention phases, subjects will be randomly allocated to receive 1 of 3 doses Namisol®: 3 mg, 5 mg, 6,5 mg (or placebo) The washout period between the intervention periods will be at least 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On each intervention day the subjects will receive the same amount of drugs in order to insure the blinding of the study
Study: NCT02726087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ministernotomy
Description: Partial upper J hemisternotomy trough 4th right intercostal space)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full sternotomy
Description: Conventional full median sternotomy
Study: NCT01395199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5mg PO initially; may be reduced to 2.5mg PO if side effects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine
Description: 5mg PO initially; may be reduced to 2.5mg PO if side effects
Study: NCT03029715

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Total intravenous anaesthesia.

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Narcotics

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Narcotics

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: Total intravenous anaesthesia

Intervention type: DRUG
Group type: OTHER
Intervention: Desflurane
Description: Inhalation anaesthesia.
Study: NCT00364520

Intervention type: OTHER
Intervention: Shanghai workers
Study: NCT05052073

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose load at rest
Description: oral glucose load (75 g) after an 12h overnight fast at rest accompanied by blood sampling and dialysate sampling (adipose tissue and skeletal muscle), and calorimetry (canopy) over three hours.

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose load at rest
Description: oral glucose load (75 g) after an 12h overnight fast at rest accompanied by blood sampling and dialysate sampling (adipose tissue and skeletal muscle), and calorimetry (canopy) over three hours.

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose load and exercise
Description: oral glucose load (75 g) after an 12h overnight fast followed by a defined (0.5 W / kg), moderate bicycle exercise i a metabolic chamber

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose load and exercise
Description: oral glucose load (75 g) after an 12h overnight fast followed by a defined (0.5 W / kg), moderate bicycle exercise i a metabolic chamber
Study: NCT02308631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY
Description: The endoscope was manipulated until the light approached the pre-set for the use of transillumination site and puncture with the Loop Fixture II gastropexy kit
Study: NCT03747042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Patients will receive a prescription for letrozole to be taken orally for 7-30 days to allow for variations in surgical scheduling. Patients are to undergo surgical resection of their tumor the day after the last dose of letrozole. Post-treatment tumor biopsies (a goal of 4-6 cores) will be obtained following 7-56 days of letrozole treatment on the day of surgery.
Study: NCT05299775

Intervention type: DIAGNOSTIC_TEST
Intervention: World Health Organization Quality of Life -Brief -Taiwan version (WHOQOL-BREF-Taiwan version)
Description: WHOQOL-BREF-Taiwan version is used to measure the quality of life in HIV infected.~Wang Qi nine kinds of TCM constitution Questionnaire is used to measure the constitution of HIV infected.
Study: NCT02245438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone-Ethinyl Estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone-Ethinyl Estradiol
Study: NCT03511053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Steroid Injection with Lavage
Description: All participants will receive a saline lavage prior to the epidural steroid injection.
Study: NCT04221763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: His-bundle pacing.
Description: Cardiac resynchronisation therapy can be achieved using biventricular pacing involving placement of three leads into the right atrium, right ventricle and coronary sinus (epicardial left ventricle). Alternatively the third lead may be placed at the bundle of His or left ventricular septum to pace the left bundle directly.
Study: NCT00626704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive dummy AMG 655 (to maintain blind)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.
Study: NCT02435108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: crizotinib 250mg bid daily
Study: NCT01825291

Intervention type: PROCEDURE
Intervention: CPAP treatment
Study: NCT02715375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CREON2000A

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CREON2000A
Study: NCT02688491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: The investigators randomly assign assay-defined high risk patients of stageIII ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation.
Study: NCT02553265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa Low-Dose
Description: 300 mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo containing an inert substance, in capsule form that does not contain an active drug ingredient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa High-Dose
Description: 600 mg/day
Study: NCT01529177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin / clomid / hCG
Description: Metformin 1000 mg daily for a week then twice daily for 2 weeks then 3 tomes daily for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate / hCG
Description: Clomiphene citrate 50 mg daily for one month, then twice daily for 2 months then 3 times per day for 3 months.
Study: NCT02485990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Study: NCT03874663

Intervention type: DEVICE
Intervention: Directly assisted oral HIV self-testing (HIVST)
Description: 1. To determine the ability of participants with unknown HIV status to correctly perform oral HIVST;~2. To compare the results of the oral HIVST with confirmatory rapid finger prick HIV test.~3. To explore participants attitudes and preferences towards oral HIVST.~4. To explore the feasibility, acceptability and appropriateness of using a mobile photo verification app to verify HIV self-testing results.
Study: NCT04271085

Intervention type: OTHER
Intervention: Observational study
Description: No intervention involved
Study: NCT00941161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin/glimepiride combination
Description: long acting metformin/glimepiride 1g/2mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: long acting metformin 1g once a day with fasting glucose 130-199mg/dL or long actin metformin 1g twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: glimepiride 2mg once a day with fasting glucose 130-199mg/dL, or glimepiride 2mg twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
Study: NCT03294226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuraGain
Description: After anesthetic induction without neuromuscular blocking agent, AuraGain is inserted.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel
Description: After anesthetic induction without neuromuscular blocking agent, I-gel is inserted.
Study: NCT01998620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademetionine 2
Description: Ademetionine 1000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 500mg po bid with general antiviral treatment for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ademetionine 1
Description: Ademetionine 2000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ademetionine 3
Description: no treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks